Raxatrigine

Raxatrigine
	242px
Systematic (IUPAC) name
	(2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
Clinical data
Routes of; administration	Oral
Identifiers
CAS Number	934240-30-9; 934240-35-4 (mesylate)
ATC code	None
PubChem	CID: 16046068
ChemSpider	13174481
Chemical data
Formula	C18H19FN2O2
Molecular mass	314.354063 g/mol
	SMILES C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N ;
	InChI InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1 ; Key:JESCETIFNOFKEU-SJORKVTESA-N ;

Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).^[1]^[2]^[3] It acts as a selective, small-molecule, state-dependent Na_v1.7 voltage-gated sodium channel blocker.^[1]^[2] In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.^[4]^{[non-primary source needed]}

References

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.